STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

HIMS CFO exercises options, sells 11,592 shares under Rule 10b5-1

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Hims & Hers Health (HIMS) reported an insider transaction by its Chief Financial Officer. On 10/17/2025, the CFO exercised stock options for 7,785 shares at $5.01 and 3,807 shares at $11.53, then sold 11,592 Class A shares at a weighted average price of $57.1275. These trades were made under a Rule 10b5-1 trading plan adopted on May 21, 2025.

Following the transactions, the CFO beneficially owned 70,232 Class A shares directly. Derivative holdings following the transactions included 174,380 options (exercise price $5.01; expiration 02/23/2032) and 56,169 options (exercise price $11.53; expiration 03/01/2033).

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Okupe Oluyemi

(Last) (First) (Middle)
2269 CHESTNUT STREET, #523

(Street)
SAN FRANCISCO CA 94123

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/17/2025 M(1) 7,785 A $5.01 78,017 D
Class A Common Stock 10/17/2025 M(1) 3,807 A $11.53 81,824 D
Class A Common Stock 10/17/2025 S(1) 11,592 D $57.1275(2) 70,232 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $5.01 10/17/2025 M(1) 7,785 (3) 02/23/2032 Class A Common Stock 7,785 $0 174,380 D
Stock Option (right to buy) $11.53 10/17/2025 M(1) 3,807 (4) 03/01/2033 Class A Common Stock 3,807 $0 56,169 D
Explanation of Responses:
1. The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $56.93 - $57.315. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. 25% of the options will vest on the twelve (12) month anniversary of the Vesting Commencement Date of January 24, 2022. The balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments measured from the twelve (12) month anniversary of the Vesting Commencement Date, subject to optionholder's continuous Service (as defined in the Plan) as of each such vesting date.
4. The options are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with 1/48th of the options vesting monthly, beginning on April 1, 2023.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Oluyemi Okupe 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HIMS disclose in this Form 4?

The CFO exercised options for 7,785 shares at $5.01 and 3,807 shares at $11.53 on 10/17/2025, then sold 11,592 shares at a $57.1275 weighted average.

Was the HIMS CFO’s trade under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 plan adopted on May 21, 2025.

How many HIMS shares did the CFO sell and at what price?

11,592 Class A shares at a weighted average price of $57.1275, with sales between $56.93 and $57.315.

How many HIMS shares does the CFO own after these transactions?

70,232 Class A shares directly, following the reported transactions.

What derivative securities remain after the transactions?

174,380 options at $5.01 expiring 02/23/2032 and 56,169 options at $11.53 expiring 03/01/2033.

What is the earliest transaction date on the Form 4 for HIMS?

10/17/2025.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

9.11B
204.92M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO